CIPLA

INTRODUCTION
Cipla exports raw materials, intermediates, prescription drugs, OTC products and veterinary products. Cipla's manufacturing facilities have been approved by the following regulatory authorities: World Health Organisation (WHO) Department of Health, Canada.

 Medicines Control Council (MCC), South Africa. Food and Drug Administration (FDA), USA. Medicines and Healthcare products Regulatory Agency (MHRA), UK. Therapeutic Goods Administration (TGA), Australia.

 Pharamaceutical Inspection Convention (PIC), Germany. National Institute of Pharmacy (NIP), Hungary. Cipla products are bought by over 170 countries located in the following regions:

Exports is as follows:
Europe (25%) US (32%) Africa (17%) Middle East (14%) Asia (7%) Australia (5%)

HISTORY
Cipla is born in 1935, he set up The Chemical, Industrial & Pharmaceutical Laboratories, which came to be popularly known as Cipla.
Cipla was formed by the Dr K.A.Hamied.

 In 1942,Cipla was accepted by Council of Scientific and Industrial Research (CSIR), In 1944, the company bought the premises at Bombay Central and decided to put up a "first class modern pharmaceutical works and laboratory." at Vikhroli.

BACKGROUND
Cipla, Indias #2 domestic pharmaceutical company. Name of the Chemical Industrial and Pharmaceutical Laboratories Ltd was changed to the Cipla in 1984. Currently Cipla has around 2200 employees and has incorporated a unique flat organizational structure.

 Cipla is known for its ability to launch several new products every year. During the year 1997-98, it launched 18 new products. It is a leading player in anti-infective and anti-asthmatic formulations & has taken a major initiative in the Anti-Aids segment.

PRODUCT
Brand % sales Market Therapeutic share segment (%) Growth (%yoy)

Ciplox Norflox

8.9 7.6

8.3 7.1 5.4

Anti-infective Anti-infective Anti-infective

4.5 5.0 7.5

Novamox 7.0

Asthalin- 3.9 Inh Novaclox 3.8

7.5
2.9

Antiasthmatic Anti-infective

17.5
15.0

ORGANISTION STRUCTURE
M K Hamied [Whole Time Director] D R Narang [Director]

Dr Y K Hamied [Chairman & Managing Director]

H Chawla [Whole Time Director]

Amar Lulla [Whole Time Director]

Dr H R Manchanda [Director]
V C Kotwal [Asst Director]

S A A Pinto [Director]

Ramesh Shroff

[Asst Director]

B K Khare [Asst Director]

MANUFACTURING PROCESS OF FORACORT FORTE

 Foracort forte is a combination product containing higher dose of formoterol (12 mcg) and budesonide (400 mcg) for management of COPD and also severe asthma. From small molecules and vaccines to biologics and cytotoxics. Methods development in the medican

 Process development if any possiblity in the manufacturing process. Transfer for filling in the rotacaps. After filling in the rotacaps it is send for packaging.